Skip to main content
OpenTrials
Completed

NCT Number: NCT01666925

Efficacy of Malaria Vaccines in Kenyan Adults

Malaria transmission is falling in some parts of Africa as bed nets and anti-malarials become more widely available. However, transmission still persists and it appears that additional control measures are required. The leading malaria vaccine candidate in development is RTS,S which has efficacy against clinical malaria measured at 30-50% in the field. This partial protection might be enhanced by combination with other components. The other vaccination approach that has produced repeatable efficacy in humans is the use of viral vectors to induce T cell responses. Previous attempts with this vaccine approach have been effective in challenge studies in Oxford, but ineffective in the field, probably because of reduced immunogenicity.

Recently, studies in Oxford, Kenya and the Gambia have shown higher levels of immunogenicity by using a chimpanzee adenovirus (ChAd63) followed by an attenuated vaccinia virus (modified vaccinia Ankara) to deliver the pre-erythrocytic antigen, multiple epitope string with thrombospondin- related adhesion protein (ME-TRAP).

The increase in immunogenicity has lead to sterile protection in 3 out of 14 volunteers and partial protection in 5 out of 14 volunteers in challenge studies.

The investigators propose a Phase 2b study of 120 healthy adult men in Kenya. The investigators will assess the efficacy and further evaluate the immunogenicity and safety profile of the vaccine regimen. The investigators also intend to assess the correlates of efficacy and natural immunity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Malaria Infections Mosquito-Borne Diseases Parasitic Diseases Protozoan Infections Vector Borne Diseases

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

KEMRI/Wellcome Trust Programme, Centre for Geographic Medicine Research - Coast

Kilifi, PO Box 230, 80108, Kenya

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Consenting adult males aged 18 - 50 years in good health.
  • Will remain resident in the study area for the study duration.
  • Able and willing (in the Investigator's opinion) to comply with all study requirements
  • Informed Consent

Exclusion criteria

  • Any significant medical disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
  • Hypersensitivity to Verorab, the trial vaccines or the antimalarial used.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, e.g. egg products, kathon, neomycin
  • History of splenectomy.
  • Haemoglobin less than 10.0 g/dl
  • Clinically significant abnormalities of laboratory screening tests (full blood count, ALT, creatinine levels).
  • Blood transfusion within the month preceding enrolment.
  • History of vaccination with previous experimental malaria vaccines or other vaccines likely to impact on findings of study (e.g. other MVA or adenovirus vectored vaccines)
  • Administration of any other vaccine or immunoglobulin within 2 weeks before vaccination.
  • HIV or Hepatitis B surface antigen seropositivity.
  • Current participation in another clinical trial or recent participation within 12 weeks of this study.
  • Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial.
  • Likelihood of travel away from the study area

Treatment and study plan

ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation

Biological

ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu

Rabies vaccine

Biological

2 x 2.5IU Verorab

Other names: Verorab

Primary outcomes

  1. Vaccine Efficacy

    Time frame: 18 weeks

    The first episode of P.falciparum infection positive by PCR, for P.falciparum.

Secondary outcomes

  1. Vaccine immunogenicity

    Time frame: 24 weeks

    Measures of immunogenicity will include:

    Ex vivo ELISPOT responses to overlapping pools of ME - TRAP peptides. Cultured ELISPOT responses to overlapping pools of ME - TRAP peptides. ICS by flow cytometry for cell mediated immune responses ELISA for antibodies to malaria antigens

  2. Reactogenicity

    Time frame: 24 weeks

    All solicited and unsolicited local and systemic vaccine- linked adverse events (AEs) including clinically significant laboratory abnormalities.

Sponsors and collaborators

Lead sponsor

University of Oxford

Other

Collaborators

  • European and Developing Countries Clinical Trials Partnership (EDCTP)

Registry information

Official study title

Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection.

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Aug 16, 2012
Registry last updated
Dec 12, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.